Fortitude Family Office’s Zenas BioPharma ZBIO Stock Holding History

Fortitude Family Office’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$736	Buy	+29	New	+$576	﹤0.01%	1864

Other funds holding ZBIO

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Torren Management San Diego, California $197M AUM

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Fortitude Family Office's ZBIO Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 29 shares worth $736. The stake represents ﹤0.01% of the portfolio and ranks #1864 among its holdings.

12 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Fortitude Family Office held 29 shares of Zenas BioPharma worth $736 as of Q2 2026.
Zenas BioPharma was a new Fortitude Family Office position in Q2 2026.
Zenas BioPharma made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1864 holding.
12 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.